Stock To Watch: Haemonetics Corporation (NYSE:HAE)


The leading market experts have placed a mean price target of $31.33 on Haemonetics Corporation (NYSE:HAE) stock. This price level, which is estimated to be attained in one-year indicates the mean of stock opinions given by the companies included in the First Call survey. The renowned research firms have predicted earnings of $0.34 a share for the upcoming quarter and $1.44 for the current fiscal. Technical View The technical analysis of Haemonetics Corporation Common plainly substantiates that the 50-day moving average of Haemonetics Corporation Common is $28.70, and stock is hovering 0.28 or +0.98% distant from $28.70. It is noted that the 200-day MA is $31.55, and Haemonetics Corporation Common stock is $-2.57 or -8.14% off from this point. Haemonetics Corporation (NYSE:HAE) 52-week high is $43.18 and the 52-week low is $25.98. This explains if the stock moves $-14.20, it will post a 52-week high. In event of $+11.55% points decline, a 52-week low will be hit. Taking the Valuation Aspect To emphasize the valuation of Haemonetics Corporation Common , shareholders can apply financial tool known as price-to-earnings ratio. This financial ratio assesses stock’s valuation by considering the relative expense of the stock. Following this ratio, Haemonetics Corporation (NYSE:HAE) ratio came in at N/A. The stock last ended the trading session at $28.98 and registered a market cap of $1.48B. To appraise firm’s growth, the shareholders take help of the Price-to-Earnings-Growth ratio. When a stock has a higher PEG ratio, it is suggestive of lower stock appreciation in approaching sessions. A stock comes in the group of undervalued stocks when its PEG ratio falls in between 0 and 1. Haemonetics Corporation (NYSE:HAE) PEG ratio is at 4.04.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 2 times, 1 visits today)